Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Australian Stock Exchange  >  Regeneus Ltd    RGS   AU000000RGS6

REGENEUS LTD

(RGS)
  Report
SummaryChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Regeneus : KYOCERA to Collaborate with Regeneus on Promising New Stem Cell-Based Therapy for Knee Osteoarthritis

share with twitter share with LinkedIn share with facebook
08/19/2020 | 09:44am EDT

Kyocera Corporation (President: Hideo Tanimoto, hereafter 'Kyocera') today announced that it has entered a license and collaboration agreement with Sydney, Australia-based Regeneus Ltd. (CEO: Leo Lee, hereafter 'Regeneus') for exclusive rights in Japan to develop, produce, and commercialize Regeneus's unique cell-preparation1 technology as a regenerative medical product for treating patients with knee osteoarthritis.

The technology licensed from Regeneus enables allogeneic mesenchymal stem cells2 to be formulated into a cell preparation that can be administered to patients. Regeneus has completed an early clinical test in Australia for patients suffering from knee osteoarthritis, with promising results.

An estimated 25 million people in Japan exhibit osteoarthritic conditions in the knee, and approximately 8 million are fully symptomatic.3 About 1.4 million in total are currently receiving treatment for arthrosis, including knee osteoarthritis, and the number increases yearly.4 Kyocera aims to develop and commercialize the cell-preparation technology as a new product for treating these patients.

Kyocera is committed to developing new technologies and products that contribute to human health and well-being. The company is currently expanding its medical and healthcare R&D activities, which include orthopedic joint replacement systems and dental implants developed through its proprietary materials and surface-processing technologies, as well as regenerative medicine and presymptomatic treatments.

About Regeneus

Regeneus Ltd (ASX:RGS) is a Sydney-based regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza and Sygenus.

Contact:

Tel: 1-800-255-6482

(C) 2020 Electronic News Publishing, source ENP Newswire


Stocks mentioned in the article
ChangeLast1st jan.
KYOCERA CORPORATION 0.16% 6301 End-of-day quote.-15.76%
REGENEUS LTD 11.54% 0.145 End-of-day quote.66.67%
share with twitter share with LinkedIn share with facebook
All news about REGENEUS LTD
08/27REGENEUS LTD (ASX : RGS) Receives Milestone Payment from Kyocera
AQ
08/24REGENEUS LTD (ASX : RGS) To present at FNN Virtual Investor Event
AQ
08/19REGENEUS : KYOCERA to Collaborate with Regeneus on Promising New Stem Cell-Based..
AQ
08/18REGENEUS LTD (ASX : RGS) US Patent for Sygenus
AQ
08/10REGENEUS LTD (ASX : RGS) and Kyocera Sign Progenza OA Deal
AQ
07/31Regeneus Ltd Quarterly Report
AW
07/27REGENEUS LTD (ASX : RGS) Progenza OA Kyocera Negotiations Update
AQ
07/10REGENEUS LTD (ASX : RGS) Featured in Morgans' 'Under The Microscope' Podcast ser..
AQ
06/03REGENEUS LTD (ASX : RGS) Director Resignation
AQ
04/28REGENEUS LTD (ASX : RGS) Quarterly Report
AQ
More news
Financials
Sales 2020 2,33 M 1,65 M 1,65 M
Net income 2020 -1,07 M -0,75 M -0,75 M
Net Debt 2020 0,14 M 0,10 M 0,10 M
P/E ratio 2020 -17,4x
Yield 2020 -
Capitalization 43,5 M 30,8 M 30,7 M
EV / Sales 2019 14,8x
EV / Sales 2020 8,39x
Nbr of Employees -
Free-Float 61,7%
Chart REGENEUS LTD
Duration : Period :
Regeneus Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers
NameTitle
Leo Lee Chief Executive Officer & Executive Director
Barry George Sechos Non-Executive Chairman
John Bird Chief Operating & Financial Officer
Graham Vesey Executive Director & Chief Scientific Officer
Charlotte Morgan Head-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
REGENEUS LTD66.67%28
GILEAD SCIENCES, INC.-7.65%75 236
REGENERON PHARMACEUTICALS50.42%61 299
VERTEX PHARMACEUTICALS-3.97%55 269
WUXI APPTEC CO., LTD.64.97%39 253
BEIGENE, LTD.81.31%27 327